|
|
Analysis of combined antibacterial of extensively drug-resistant Acinetobacter baumannii in vitro |
MA Dongmei TAO Qingchun QI Hongwei |
Department of Clinical Laboratory, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China |
|
|
Abstract Objective To study antibacterial effect of Shuanghuanglian combined with minocycline and Piperacillin /Taz-obactam and Cefoperazone / Sulbactam on extensively drug-resistant Acinetobacter baumannii in vitro. Methods A total of 30 strains extensively drug-resistant Acinetobacter baumannii were collected from clinical specimens from October 2016 to June 2017 in Beijing University of Chinese Medicine Third Affiliated Hospital. The minimum inhibitory concentration (MIC) of Shuanghuanglian and minocycline, Piperacillin / Tazobactam, Cefoperazone / Sulbactam (Cefoperazone / Sulbactam) in 30 strains extensively drug-resistant Acinetobacter baumannii was tested by the broth dilution method, and the partial inhibitory concentration (FIC) index was calculated, and the combined bacteriostasis effect of Chinese and Western medicine was determined. Results The FIC index of Shuanghuanglian combined with minocycline: 0.5-1 accounted for 6.7%, >1-2 accounted for 63.3%, and >2 accounted for 30.0%; the FIC index of Shuanghuanglian combined with Piperacillin / Tazobactam: 0.5-1 accounted for 16.7%, >1-2 accounted for 83.3%; the FIC index of Shuanghuanglian combined with Cefoperazone / Sulbactam: ≤ 0.5 accounted for 23.3%, 0.5-1 accounted for 73.3%, >1-2 accounted for 3.3%. Conclusion Shuanghuanglian combined with minocycline and Piperacillin / Tazobactam has a non-independent and antagonistic effect on the extensively drug-resistant Acinetobacter baumannii, and the combined antibacterial effect in vitro is poor. The combined antibacterial effect of Shuanghuanglian combined with Cefoperazone / Sulbactam is better.
|
|
|
|
|
[1] 胡付品,朱德妹,汪复,等.2014年CHINET细菌耐药性监测[J].中国感染与化疗杂志,2015,15(5):401-410.
[2] 胡付品,朱德妹,汪复,等.2015年CHINET细菌耐药性监测[J].中国感染与化疗杂志,2016,16(6):685-694.
[3] 胡付品,郭燕,朱德妹,等.2016年CHINET细菌耐药性监测[J].中国感染与化疗杂志,2017,17(5):481-491.
[4] 李春娜,刘洋洋,李鹏收,等.中药复方双黄连剂型研究[J].中国中医药科技,2015,22(1):115-117.
[5] 刘会丽.双黄连的药理作用及临床应用研究[J].医药前沿,2016,6(6):367-368.
[6] 王辉,郭萍,孙宏莉,等.碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J].中华检验医学杂志,2006,29(12):1062-1073.
[7] 胡超,赵子文.多重耐药鲍曼不动杆菌耐药机制及治疗进展[J].广东医学,2015,36(12):1803-1806.
[8] 陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85.
[9] 白艳,孙艳,王瑾,等.多黏菌素E联合其他抗菌药物对多重耐药鲍曼不动杆菌的体外抗菌活性研究[J].中国药学杂志2015,50(5):427-430.
[10] 陈华利,刘晓金,高燕,等.双黄连口服制剂药理作用及质量评价方法综述[J].辽宁中医药大学学报,2016,18(7):161-163.
[11] 梁华,彭小宝,杨军平,等.清开灵、双黄连联合头孢哌酮-舒巴坦钠对产ESBLs肺炎克雷伯菌抗菌作用研究[J].实验与检验医学,2016,34(6):723-727.
[12] 李娜,刘桢宇,陈春林.双黄连联合抗生素抗菌作用及机制研究进展[J].宜春学院学报,2017,39(9):16-19.
[13] 张伟,包俊.双黄连联合氯唑西林钠对金葡球菌耐药株的抗菌作用研究[J].中国中医药科技,2013,20(3):245-246.
[14] 徐海瑛,王树芳,王丽,等.双黄连口服液联合庆大霉素的体外抗菌作用研究[J].医药导报,2013,32(1):19-22.
[15] Higgins PG,Wisplinghoff H,Stefanik D,et al. In vitro activities of the beta-lactamase inhibitors clavulanic acid,sulbactam,and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains [J]. Antimicrob Agents Chemother,2004,48(5):1586-1592.
[16] Levin AS. Multiresistant acinetobacter infections:a role for sulbactam combinations in overcoming an emerging worldwide problem [J]. Clin Microbiol Infect,2002,8(3):144-153.
[17] Levin AS,Levy CE,Manrique AE,et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam[J]. Int J Antimicrob Agents,2003,21(1):58-62.
[18] 李娅娟,刘蓬蓬,李萍,等.头孢哌酮/舒巴坦对革兰阴性菌的抗菌活性[J].中华医院感染学杂志,2006,16(5):554-556.
[19] 廖光荣,李娜,黄艳芳,等.头孢哌酮舒巴坦联合其他抗菌药物治疗鲍曼不动杆菌感染的系统评价[J].成都医学院学报,2016,11(1):52-57.
[20] 覃茂安.头孢哌酮钠舒巴坦钠治疗37例社区获得性肺炎的效果观察[J].中外医学研究,2017,15(11):114-115.
[21] 黄瑞玉,穆小萍,柏彩英,等.连翘对多药耐药鲍曼不动杆菌主动外排泵编码基因adeB的影响[J].中国病原生物学杂志,2011,6(2):111-114.
[22] 吴峥嵘,何明.双黄连对多重耐药大肠埃希菌抗菌增敏作用及机制研究[J].辽宁中医药大学学报,2013,15(8):31-33. |
|
|
|